Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
1.16 USD 0.04 ( 3.57%)
Last update at 2026-11-18T21:00:00Z
VOLUME
132253
Market Cap
25.18M

Momentum Score

…

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.08
Low
1.20
High
52 Week Price Range
0.31
Low
1.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Femasys Inc is a clinical-stage medical device company focused on developing minimally invasive diagnostic and therapeutic solutions for women's reproductive health. Long-term growth may be supported by demographic trends increasing demand for gynecological and fertility care, successful regulatory clearances, and commercial adoption of its product pipeline. Investors may find exposure to niche women's-health innovation and potential upside if clinical milestones and market launches progress.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.12
Dividend Yield
-
Revenue TTM
2.29M
Revenue Per Share
0.06
Gross Profit TTM
1.42M
Debt / Equity
0.80
ROE
-455.80%
Net Debt
-4.57M
ROCE
-97.94%
Diluted EPS TTM
-0.47

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -18.63M -18.81M -14.24M -11.39M -7.53M
Net income -18.63M -18.82M -14.25M -11.39M -7.54M
Selling general administrative 6.65M 6.33M 6.86M 5.43M 4.26M
Selling and marketing expenses 4.44M 4.03M 0.65M 0.56M 0.21M
Gross profit 1.42M 1.08M 0.69M 0.76M 0.81M
Reconciled depreciation 0.85M 0.87M 0.88M 0.89M 0.96M
Ebit -16.74M -17.20M -14.08M -11.60M -8.34M
Ebitda -15.89M -16.33M -13.17M -10.81M -6.92M
Depreciation and amortization 0.85M 0.87M 0.91M 0.79M 1.41M
Operating income -17.59M -17.79M -14.51M -11.60M -8.34M
Other operating expenses 19.88M 19.41M 15.58M 12.81M 9.52M
Interest expense 1.89M 1.60M 0.17M 0.01M 0.02M
Tax provision 0.00M 0.01M 0.00M 0.01M 0.00M
Interest income 0.10M 0.58M 0.35M 0.23M 0.00M
Net interest income -1.79M -1.02M 0.34M 0.21M -0.02M
Income tax expense 0.00M 0.01M 0.00M 0.01M 0.00M
Total revenue 2.29M 1.63M 1.07M 1.21M 1.18M
Total operating expenses 19.01M 18.87M 15.20M 12.36M 9.15M
Cost of revenue 0.87M 0.54M 0.38M 0.44M 0.37M
Total other income expense net -1.04M -1.02M 0.27M 0.21M 0.80M
Net income from continuing ops -18.63M -18.82M -12.73M -11.39M -7.54M
Net income applicable to common shares - - - -11.39M -7.54M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 20.72M 12.45M 27.76M 16.90M 28.58M
Intangible assets 0.13M 0.07M - 0.00M 0.03M
Other current assets 0.83M 1.04M 0.70M 0.66M 0.56M
Total liab 14.85M 10.14M 9.40M 1.65M 2.24M
Total stockholder equity 5.87M 2.30M 18.35M 15.24M 26.33M
Other current liab 1.32M 1.24M 1.51M 0.50M 0.05M
Common stock 0.06M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.06M 0.02M 0.02M 0.01M 0.01M
Retained earnings -145.83M -127.20M -108.38M -94.13M -82.74M
Other liab - - - 0.10M 0.15M
Other assets - 0.00M - 0.96M 0.66M
Cash 9.27M 3.45M 21.72M 12.96M 24.78M
Total current liabilities 3.64M 8.58M 3.05M 1.53M 1.69M
Current deferred revenue - - - - 0.60M
Net debt -4.57M 3.99M -15.02M -12.42M -23.79M
Short term debt 0.49M 5.92M 0.41M 0.52M 0.59M
Short long term debt - 5.41M - 0.19M 0.18M
Short long term debt total 4.70M 7.44M 6.70M 0.54M 0.99M
Other stockholder equity 151.64M 127.62M 123.93M 109.37M 109.06M
Property plant equipment - - - 1.80M 2.26M
Total current assets 16.46M 8.02M 23.18M 14.13M 25.63M
Net tangible assets - - - 15.24M 26.31M
Net receivables 0.62M 0.49M 0.10M 0.08M 0.08M
Long term debt 3.18M - 4.26M - -
Inventory 5.74M 3.05M 0.67M 0.44M 0.21M
Accounts payable 1.83M 1.42M 1.14M 0.51M 0.45M
Accumulated other comprehensive income - 1.86M 2.79M - -28.58M
Non currrent assets other 0.94M 0.95M 1.09M 0.96M 0.66M
Non current assets total 4.27M 4.42M 4.58M 2.76M 2.95M
Capital lease obligations 1.52M 2.04M 2.44M 0.40M 0.81M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.85M -0.19M -0.41M -0.31M
Change to liabilities - - - 0.07M -0.23M
Total cashflows from investing activities -0.63M -0.85M -0.14M -0.41M -0.31M
Net borrowings 4.15M 0.00M 6.22M -0.53M -0.46M
Total cash from financing activities 25.14M 2.03M 20.18M -0.68M 29.70M
Change to operating activities - - - -0.30M -0.47M
Net income -18.63M -18.82M -14.25M -11.39M -7.54M
Change in cash 5.81M -18.26M 8.75M -11.82M 21.46M
Begin period cash flow 3.45M 21.72M 12.96M 24.78M 3.32M
End period cash flow 9.27M 3.45M 21.72M 12.96M 24.78M
Total cash from operating activities -18.69M -19.44M -11.28M -10.73M -7.93M
Issuance of capital stock 19.52M 2.03M 3.98M 0.08M 31.74M
Depreciation 0.80M 0.87M 0.91M 0.89M 0.96M
Other cashflows from investing activities -0.11M -0.09M - - -
Change to inventory -2.69M -2.38M -0.24M -0.23M -0.08M
Change to account receivables -0.13M 0.01M -0.02M 0.01M 0.04M
Other cashflows from financing activities -1.95M 0.00M 2.39M -0.23M -1.58M
Change to netincome - - - 0.23M -0.62M
Capital expenditures 0.53M 0.76M 0.14M 0.41M 0.31M
Change in working capital -2.06M -3.14M 1.22M -0.46M -0.73M
Stock based compensation 0.79M 0.44M 0.68M 0.22M 0.19M
Other non cash items 0.40M 1.20M 0.16M 0.01M -0.82M
Free cash flow -19.22M -20.21M -11.42M -11.14M -8.24M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FEMY
Femasys Inc
0.04
3.57%
1.16 - - 10.98 4.42 9.31 0.24
ISRG
Intuitive Surgical Inc
-9.58
2.23%
420.95 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme
2.30
1.17%
199.30 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA
1.01
1.03%
99.22 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company
-
-%
216.08 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

Femasys Inc

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

3950 Johns Creek Court, Suwanee, GA, United States, 30024

770 500 3910

51

Name Title Year Born
Ms. Kathy Lee-Sepsick Founder & CEO and Pres 1967
Mr. Daniel Scott Currie SVP of Operations & Sec. 1964
Mr. Dov Elefant Chief Financial Officer 1967
Ms. Mary An Merchant J.D., Ph.D. VP of Counsel & Intellectual Property NA
Mr. Steven P. Damon VP of Bus. Devel. 1956
Mr. Todd A. Creech MBA Chief Financial Advisor 1968
Dr. Jeffrey Marcus M.D., M.S. Chief Medical Advisor NA
Dr. Edward G. Evantash M.D. Chief Medical Officer 1963
Ms. Christine Thomas Sr. VP of Regulatory & Clinical Affairs NA
Ms. Kathy Lee-Sepsick M.B.A. Founder, President, CEO & Director 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…